Frequently Ask Question

Will Boliss work for type 2 diabetics?
Boliss has had mixed results for insulin dependent and non- insulin dependent type 2s. Insulin dependent type 2s have had much more success then those type 2s who do not use insulin, however, we can not guarantee success. Use at your own discretion. Boliss should not be taken by anyone with a sodium restrictive diet.
Does Boliss work with every insulin ?

Yes

Can Boliss drop my hemoglobin A1C percentage?

Though we didn’t run a robust clinical trial testing Boliss’s impact on A1C percentages, we measured the hemoglobin A1C levels for Tommy and Gary (Boliss's founders) who consistently took the product over a period of several months. Over a 4-to-6-month period, they experienced an average A1C percentage reduction of nearly 0.1 percent per month. Tommy and Gary's A1C percentages have remained at lifelong lows.

Our Story

Boliss SOS was founded by Dr. Gary Ritz and his son, Tommy Ritz. Gary has been living with T1D since 1984, and Tommy has been a T1D since 1998. Tired of their daily battles to manage their diabetes, which often resulted in prolonged periods of high blood sugar, the father/son duo sought a better way to combat hyperglycemia. It took many years to identify and refine a solution to the problem, eventually leading to the development of Boliss SOS. Boliss SOS is a supplement that, when used in conjunction with insulin and water, returned their high blood sugar levels to normal in a much faster time frame. They had several of their friends and family members with T1D try it, and found it worked for them as well. Boliss SOS is an all-natural formulation. All of its active ingredients are widely available in food products and routinely ingested in some form by most people. Both Gary and Tommy used Boliss SOS regularly to help manage their diabetes, and want to bring Boliss SOS to the rest of the diabetic world.

The Boliss SOS Team

Investors/Partners

RDR Therapeutics founders, the manufacturer of Boliss SOS, working in conjunction with Dr. Jason McDevitt at the College of William & Mary, developed a formulation that safely and economically works in conjunction with insulin to reduce the duration and magnitude of hyperglycemic events. This patented technology was licensed from William & Mary to the company.